Lilly’s New Pill Achieves 7.9 Percent Weight Loss in Diabetics in Major Study
Eli Lilly’s experimental oral medication, orforglipron, has demonstrated promising results in a late-stage clinical trial, leading to up to 7.9% weight loss in patients with type 2 diabetes.
Unlike injectable treatments, orforglipron is a once-daily pill, offering a more convenient option for patients. The trial also showed significant reductions in HbA1c levels, a key marker of blood sugar control.
Common side effects included nausea (13–18%), diarrhea (19–26%), and vomiting (5–14%), with about 8% of participants discontinuing the treatment at the highest dose.
Eli Lilly plans to seek regulatory approval for orforglipron by the end of 2025, aiming to provide a scalable and accessible treatment option for weight management and diabetes care.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-06-19
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
The $6 Billion Gold Rush: Generic Semaglutide Set to Reshape Global Pharma After Patent Cliff
-
The Pill That Could Swallow the Needle: Novo Nordisk Launches Oral Wegovy in U.S. Weight-Loss Revolution
-
AstraZeneca Targets Year-End Filing for Novel Hypertension Drug Baxdrostat
-
Aficamten Beats Metoprolol in Obstructive HCM, Strengthening Case Ahead of FDA Decision
-
Merck to Lay Off 150 Workers at US Gardasil Plant Amid Sales Weakness
-
FDA Clears Sanofi’s Wayrilz (rilzabrutinib) for Adult ITP; U.S. Launch in September
-
Glenmark Recalls Over 110000 Bottles of BP and COPD Drugs in US Due to Safety Concerns
-
Parliamentary Panel Urges Expanded Price Controls as Dozens of Cancer Drugs Remain Unregulated
-
Novo Nordisk Reports Theft of Six Drug Batches in India Authorities Warn of Severe Patient Safety Risks
-
Roche Keeps German Diagnostics Investment
Recommend Reading
-
Pfizer Warns Germany Over Drug-Pricing Policy
-
India Raises Cancer Drug Price Caps by 50%
-
NHU and Sinopec Advance Liquid Methionine Project
-
U.S. Onshoring Debate Exposes API Raw-Material Gap
-
BASF Raises API and Excipient Prices
-
Cost Support: Adipic Acid Sees Rising Prices
-
China Activates Blocking Rules in Response to U.S. Sanctions on Petrochemical Firms
-
Indorama Corporation Acquires 100% Stake in Anyang Zhongying Fertilizer
-
U.S. Chemical Companies Are Benefiting from This Feedstock Shock
-
Rising Costs and Tightened Supply Lead to a Sharp Increase in Phthalic Anhydride Prices